Pfizer's ex-chair and chief executive Ian Read and Frank D'Amelio – previously the drugmaker's finance chief – have issued a ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

Expectations for both companies are really high. Morningstar estimates the GLP-1 drug market will be worth $200bn by 2031, and analysts expect Eli Lilly and Novo Nordisk to take the lion’s share of it ...

Pfizer's shares have fallen more than 9% in the past year and trade at around half of their pandemic-era highs as sales of ...

The prescription-free test you can take at home will help discern which respiratory virus you have, as symptoms often overlap ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

Pfizer's former CEO and Chair Ian Read and ex-CFO Frank D'Amelio said in a statement that they will not be involved with ...

Former Pfizer Inc. executives Ian Read and Frank D’Amelio have decided “not to be involved” in Starboard Value’s activist ...

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

$468 $279 for your first year, equivalent to $23.25 per month. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Take this offer before 24 October.

Guggenheim Securities, LLC is issuing a statement on behalf of former Pfizer CEO Ian Read and former Pfizer CFO Frank D'Amelio: We have decided not to be involved in the efforts of Starboard Value ...